Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction

Lawrence Einhorn, S. D. Williams, I. Mandelbaum, J. P. Donohue

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Platinum combination chemotherapy will regularly produce a 70% complete response rate in testicular cancer. Many patients failing to achieve complete remission can still be rendered disease-free with surgical resection of residual localized disease. Twenty-one patients underwent resection for residual pulmonary lesions and 41 underwent lymphadenopathy for persistent retroperitoneal disease. There were no characteristic radiographic findings for fibrous tissue versus mature teratoma versus carcinoma. Although elevated HCG or AFP levels indicated the presence of carcinoma, negative HCG and AFP did not rule out such a diagnosis as 12 of 22 resected carcinoma patients were seronegative. Of 35 patients, 31 (89%) with fibrous tissue or mature teratomas and all four patients with immature teratomas have been continuously free of disease with a minimal postoperative follow up time of six months. However, only two of 22 patients with resected carcinomas have been continuously disease-free. Postoperative chemotherapy for mature teratoma or fibrous tissue is probably not necessary. However, we feel that further aggressive chemotherapy is needed in the resected carcinoma patient with at least two courses of platinum combination chemotherapy. Surgical resection of residual disease following chemotherapy-induced cytoreduction with platinum combination chemotherapy may be therapeutic in some cases and helps to define the optimal subsequent treatment strategy.

Original languageEnglish
Pages (from-to)904-908
Number of pages5
JournalCancer
Volume48
Issue number4
StatePublished - 1981

Fingerprint

Testicular Neoplasms
Teratoma
Carcinoma
Combination Drug Therapy
Platinum
Drug Therapy
Lung
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Einhorn, L., Williams, S. D., Mandelbaum, I., & Donohue, J. P. (1981). Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer, 48(4), 904-908.

Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. / Einhorn, Lawrence; Williams, S. D.; Mandelbaum, I.; Donohue, J. P.

In: Cancer, Vol. 48, No. 4, 1981, p. 904-908.

Research output: Contribution to journalArticle

Einhorn, L, Williams, SD, Mandelbaum, I & Donohue, JP 1981, 'Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction', Cancer, vol. 48, no. 4, pp. 904-908.
Einhorn, Lawrence ; Williams, S. D. ; Mandelbaum, I. ; Donohue, J. P. / Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. In: Cancer. 1981 ; Vol. 48, No. 4. pp. 904-908.
@article{f36f59c6316d43dbb54f44766f5a5cab,
title = "Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction",
abstract = "Platinum combination chemotherapy will regularly produce a 70{\%} complete response rate in testicular cancer. Many patients failing to achieve complete remission can still be rendered disease-free with surgical resection of residual localized disease. Twenty-one patients underwent resection for residual pulmonary lesions and 41 underwent lymphadenopathy for persistent retroperitoneal disease. There were no characteristic radiographic findings for fibrous tissue versus mature teratoma versus carcinoma. Although elevated HCG or AFP levels indicated the presence of carcinoma, negative HCG and AFP did not rule out such a diagnosis as 12 of 22 resected carcinoma patients were seronegative. Of 35 patients, 31 (89{\%}) with fibrous tissue or mature teratomas and all four patients with immature teratomas have been continuously free of disease with a minimal postoperative follow up time of six months. However, only two of 22 patients with resected carcinomas have been continuously disease-free. Postoperative chemotherapy for mature teratoma or fibrous tissue is probably not necessary. However, we feel that further aggressive chemotherapy is needed in the resected carcinoma patient with at least two courses of platinum combination chemotherapy. Surgical resection of residual disease following chemotherapy-induced cytoreduction with platinum combination chemotherapy may be therapeutic in some cases and helps to define the optimal subsequent treatment strategy.",
author = "Lawrence Einhorn and Williams, {S. D.} and I. Mandelbaum and Donohue, {J. P.}",
year = "1981",
language = "English",
volume = "48",
pages = "904--908",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction

AU - Einhorn, Lawrence

AU - Williams, S. D.

AU - Mandelbaum, I.

AU - Donohue, J. P.

PY - 1981

Y1 - 1981

N2 - Platinum combination chemotherapy will regularly produce a 70% complete response rate in testicular cancer. Many patients failing to achieve complete remission can still be rendered disease-free with surgical resection of residual localized disease. Twenty-one patients underwent resection for residual pulmonary lesions and 41 underwent lymphadenopathy for persistent retroperitoneal disease. There were no characteristic radiographic findings for fibrous tissue versus mature teratoma versus carcinoma. Although elevated HCG or AFP levels indicated the presence of carcinoma, negative HCG and AFP did not rule out such a diagnosis as 12 of 22 resected carcinoma patients were seronegative. Of 35 patients, 31 (89%) with fibrous tissue or mature teratomas and all four patients with immature teratomas have been continuously free of disease with a minimal postoperative follow up time of six months. However, only two of 22 patients with resected carcinomas have been continuously disease-free. Postoperative chemotherapy for mature teratoma or fibrous tissue is probably not necessary. However, we feel that further aggressive chemotherapy is needed in the resected carcinoma patient with at least two courses of platinum combination chemotherapy. Surgical resection of residual disease following chemotherapy-induced cytoreduction with platinum combination chemotherapy may be therapeutic in some cases and helps to define the optimal subsequent treatment strategy.

AB - Platinum combination chemotherapy will regularly produce a 70% complete response rate in testicular cancer. Many patients failing to achieve complete remission can still be rendered disease-free with surgical resection of residual localized disease. Twenty-one patients underwent resection for residual pulmonary lesions and 41 underwent lymphadenopathy for persistent retroperitoneal disease. There were no characteristic radiographic findings for fibrous tissue versus mature teratoma versus carcinoma. Although elevated HCG or AFP levels indicated the presence of carcinoma, negative HCG and AFP did not rule out such a diagnosis as 12 of 22 resected carcinoma patients were seronegative. Of 35 patients, 31 (89%) with fibrous tissue or mature teratomas and all four patients with immature teratomas have been continuously free of disease with a minimal postoperative follow up time of six months. However, only two of 22 patients with resected carcinomas have been continuously disease-free. Postoperative chemotherapy for mature teratoma or fibrous tissue is probably not necessary. However, we feel that further aggressive chemotherapy is needed in the resected carcinoma patient with at least two courses of platinum combination chemotherapy. Surgical resection of residual disease following chemotherapy-induced cytoreduction with platinum combination chemotherapy may be therapeutic in some cases and helps to define the optimal subsequent treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=0019418652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019418652&partnerID=8YFLogxK

M3 - Article

C2 - 6168361

AN - SCOPUS:0019418652

VL - 48

SP - 904

EP - 908

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -